The efficacies of several dosage schedules, productive of plasma levels of cefotiam and cefazolin of short and long duration and starting at three different times (3, 18, and 30 h) after infection, were examined in experimental pneumonia caused by Klebsiella pneumoniae DT-S in mice. With each of the multiday regimens there was a large segment of the day when plasma levels fell below assayable concentrations. In all cases, cefotiam proved about eight times as active as cefazolin, indicating that the potent in vitro antibacterial activity of cefotiam was well reflected in the therapeutic effect in this model infection. As judged by the total dose administered, the regimen of cefotiam producing a low but sustained plasma level gave better therapeutic effects than that exhibiting a high but transient plasma level. The cefotiam levels in the plasma of mice that received the regimen effective when initiated at 18 h after infection were less than the expected levels in humans after intravenous infusion of the usual clinical dose.
The efficacies of several dosage schedules, productive of plasma levels of cefotiam and cefazolin of short and long duration and starting at three different times (3, 18 , and 30 h) after infection, were examined in experimental pneumonia caused by Klebsiella pneumoniae DT-S in mice. With each of the multiday regimens there was a large segment of the day when plasma levels fell below assayable concentrations. In all cases, cefotiam proved about eight times as active as cefazolin, indicating that the potent in vitro antibacterial activity of cefotiam was well reflected in the therapeutic effect in this model infection. As judged by the total dose administered, the regimen of cefotiam producing a low but sustained plasma level gave better therapeutic effects than that exhibiting a high but transient plasma level. The cefotiam levels in the plasma of mice that received the regimen effective when initiated at 18 h after infection were less than the expected levels in humans after intravenous infusion of the usual clinical dose.
Aminoglycoside antibiotics have been used xwidely as first-line agents in the treatment of Klebsiella pneumonias. These antibiotics, however, have significant side effects. Other broadspectrum antimicrobial agents with marked activity against Klebsiella have been introduced recently. These agents include cefazolin (7), cefmetazole (8) , cefamandole (13) , and cefotiam (10) . Cefotiam, 7- (10) . The present report compares the therapeutic activities of cefotiam and cefazolin in experimental pneumonias caused by Klebsiella pneumoniae DT-S. The murine model described previously (6) was employed for the evaluation.
MATERLALS AND METHODS
Respiratory tract infection. Experimental pneumonia was induced in mice as described previously (6) . Four-week-old Slc:ICR male mice, weighing 18 to 25 g, were infected with K. pneumoniae DT-S by the aerosol method, resulting in deposition of about 104 colony-forming units per lung.
Treatment. Cefotiam was prepared by Takeda Chemical Industries, Ltd., Osaka, Japan. Cefazolin (Cefamezin, Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan) was obtained from a commercial source. They were dissolved in 0.85% NaCl and injected subcutaneously (0.1 ml per mouse) following the schedules presented in each experiment (see Tables 1 to 4 and Fig. 1 and 2 ). The minimum inhibitory concentrations and minimum bactericidal concentrations (10) against K. pneumoniae DT-S were 0.1 and 0.2 ug/ml for cefotiam and 1.56 and 3.13 ,tg/ml for cefazolin, respectively. Evaluation of efficacy. Deaths of mice were recorded daily for 7 or 8 days. In the therapeutic tests, surviving animals were sacrificed 8 days after infection for gross pulmonary pathology and recovery of bacteria from the lung. For the latter purpose, the lungs were homogenized in 4 Effect of dosage schedule. The protective effect of cefotiam in several dosage schedules was studied (Table 2) . Cefotiam was administered subcutaneously one to eight times at 30-min intervals starting at 3 h after infection. Although the 50% survival dose for an eight-dose regimen was smaller than those for any other injection schedules, the 90% survival doses were almost the same for each dosage regimen. The cefotiam levels in plasma of mice after single or repeated subcutaneous administrations in doses which produced 85 to 90% protection (total dose, 160 mg/kg) are presented in Fig. 1 . A single subcutaneous administration of 160 mg of cefotiam per kg gave an extremely high plasma level of 110 pg/mI at 15 min, followed by a rapid fall. Two injections of 80 mg/kg, four doses of 40 mg/ kg, and eight doses of 20 mg/kg provided plasma levels of about 30 ug/ml for 1 h, about 20 pg/ml for 2 h, and about 10 ug/ml for 4 h, respectively. The cefotiam levels in the plasma of mice were less than the expected levels in humans after intravenous infusion of the clinical dose (N. Ya- The effects of the dosage schedule orstherapeutic activities of cefotiam in the model infection were further studied (Table 3) . Therapy was initiated at 30 h after infection. Two dosing series of cefotiam, each consisting of one to eight injections at 30-min intervals, were given daily at 8 a.m. and 4 p.m., respectively, for 7 days. The total amount of the cephalosporin administered in a dosing series was 160 or 320 mg/kg. With a total dose of 160 mg/kg per dosing series, four regimens tested produced similar therapeutic responses. In the case of a total dose of 320 mg/ kg per dosing series, however, eight 40-mg/kg doses gave a better eradication rate of the challenge organisms from the lungs of mice than any other injection schedule.
Therapeutic effect (two dosing series per day). With the objective of maintaining the cephalosporin levels in plasma for about 4 h, the mode of administration consisting of eight subcutaneous injections at 30-min intervals was employed instead of a single bolus injection. Two series of medications were given daily at 8 a.m. and 4 p.m. for 7 days. Therapy was initiated at 18 or 30 h after infection. In both instances, cefotiam proved about nine times as effective as cefazolin, as judged by the comparative 50% clearance doses (Table 4 ). The time effect of the initiation of therapy in the course of the disease, which had already been noted in the experiment described above (Table 1) , was also evident in this experiment. As judged by the comparative 50% clearance doses, the effectiveness oftherapy starting at 30 h was about one-third of that initiated at 18 h.
Bacterial numbers in the lung after medication. Two dosing series of cefotiam, each consisting of eight doses of 20 mg/kg (total dose, 160 mg/kg) at 30-min intervals, were given starting at 18 and 26 h after infection, respectively (Fig. 2) . The number of bacteria in the lung decreased to nearly 1/100 of the pretreatment level at 4 h after the onset of the first series of medication and thereafter tended to increase gradually. The number of bacteria in the lung at 4 h after the onset of the second dosing series decreased to approximately 1/1,000 of the pretreatment level. DISCUSSION The amounts of cefotiam and cefazolin required for obtaining therapeutic effects in the model infection used were considerably larger than that of kanamycin (6 depend on the differences in the fate of these Slc:ICR mice, higher peak levels and longer duantibiotics in plasma and, especially, in the lungs ration of detectable levels in the lungs were of mice after medication. With subcutaneous produced than with cefotiam and cefazolin ( suggest that penetration ofthese cephrealosporins into the respiratory secretions in mice xd < r < 3 s < 1S much inferior to that of kanamycin. Transport S g z < < >D: =~~~~of cephalosporins from the blood to bronchial secretions in humans is reported to be inferior to that of aminoglfcosides (5, 14) . In the present study, only the plasma levels of the antibiotic ao -Z 9.3
were foit owed. Owing to the blood-broncho-alx,D U* D veolar barrier (14) , however, the plasma levels vivo effectiveness obtained here, but this will be extremely difficult.
The amounts of the cephalosporins required for obtaining a definite therapeutic effect in the model infection were also markedly larger than the usual clinical doses. Comparison of the blood level-time curves ofthese cephalosporins in mice and humans receiving comparable doses per kilogram of body weight, however, reveals marked differences in the two species (1, 11, 15) . In mice, the peak level in plasma is much lower and the duration of measurable concentrations is much shorter than those in humans. This suggests that the concentration and duration of these antibiotics in infected sites of mice are much lower and shorter than those in comparable conditions in humans. On the other hand, the cefotiam levels in the plasma of mice were less than the expected levels in humans after intravenous infusion of the usual clinical dose. Therefore, it may not be reasonable to directly compare the therapeutic doses ofthe cephalosporins, in terms of milligrams per kilogram of body weight, obtained in the murine model infection with those 00000 0000 00000 0000
C9I " cO CO CO1 To predict adequately the clinical effectiveness of antimicrobial agents, it is desirable to test their activities not only in appropriate infection models but also with pertinent modes of medication. In the present study, an attempt, although a rough one, was made to reduce marked differences between pharmacokinetic characteristics of the cephalosporins in the blood of mice and those in humans. An examination of therapeutic activities of the cephalosporins in the murine model of pneumonia with the treatment schedules, which provide blood levels of the antibiotics resembling more closely those in humans, is an interesting future problem. It is still a matter of controversy whether either of the two modes of antibiotic administration, a single bolus injection or intravenous infusion, would be preferable to obtain an optimal clinical result (9) . The results obtained in the present study favor the latter regimen.
Pneumonia caused by K. pneumoniae in humans is often difficult to treat (12) . The murine pneumonia caused by K. pneumoniae DT-S also proved difficult to treat, especially when therapy was begun 30 h after infection. A further study is needed to determine the optimum treatment schedules required for complete cure of the experimental pneumonia caused by K. pneumoniae DT-S in mice.
LITERATURE CITED
